Semaglutide News and Research

Latest Semaglutide News and Research

Oral diabetes and obesity meds danuglipron and orforglipron show promise but have gastrointestinal drawbacks

New orally-administered GLP-1 receptor agonists danuglipron and orforglipron show promise in treating type 2 diabetes and obesity, according to a systematic review. While effective in glycemic control and weight reduction, these drugs come with gastrointestinal side effects that may lead to treatment discontinuation.

17 Oct 2023

Skyrocketing demand for weight-loss drugs prompts calls for informed prescribing

The study reveals a significant increase in the usage of GLP-1 receptor agonists, particularly Ozempic and Trulicity, for weight management and Type 2 diabetes in the U.S. from 2014 to 2022. Amidst rapid growth and shortages, the paper calls for evidence-based decision-making to ensure stable medication supply and effective treatment.

17 Oct 2023

Tirzepatide boosts weight loss in lifestyle intervention patients, but comes with a catch

In a groundbreaking 84-week-long study, researchers found that tirzepatide, a medication initially designed for treating type 2 diabetes, significantly bolstered weight loss in overweight and obese patients already on intensive lifestyle programs. While the drug showed promise in further reducing body weight and improving cardiometabolic factors, mild to moderate gastrointestinal side effects were the most common drawback.

16 Oct 2023

Presidential advisory by the American Heart Association: connecting cardiovascular, kidney, and metabolic health

The interplay among chronic kidney disease, metabolic risk factors, and the cardiovascular system.

11 Oct 2023

Black Chokeberry (Aronia melanocarpa) diabetes benefits: Hope or hype?

Researchers compared the effects of fermented and non-fermented Aronia melanocarpa berries on glycemic markers in Type 2 Diabetes Mellitus patients. Despite the berries' high antioxidant potential and past studies suggesting benefits, this rigorous trial found no significant impact on waist circumference, insulin sensitivity, or glucose levels.

10 Oct 2023

Health experts redefine cardiovascular disease risk, prevention and management

Health experts are redefining cardiovascular disease (CVD) risk, prevention and management, according to a new American Heart Association presidential advisory published today in the Association's flagship journal Circulation.

9 Oct 2023

How is TikTok's #Ozempic trend impacting diabetes patients?

A recent study analyzed TikTok videos with the hashtag "Ozempic," highlighting the platform's influence on promoting the weight loss drug. The surge in popularity resulted in medication shortages for diabetes patients, emphasizing the need for careful monitoring and collaboration among health professionals and social media platforms.

5 Oct 2023

GLP-1 weight loss drugs linked to heightened GI risks, says new study

Study from JAMA reveals that users of GLP-1 agonists, recent drugs for weight management, show a heightened risk of gastrointestinal complications like intestinal obstruction, gastroparesis, and pancreatitis. Though these effects are rare, those considering these drugs for weight loss should weigh the benefits against potential risks, especially if not using them for diabetes.

5 Oct 2023

New findings about nerve pathways to brown fat could lead to obesity treatments

A UCLA-led team of researchers has found nerve pathways that supply brown adipose tissue (BAT), a type of tissue that releases chemical energy from fat metabolism as heat – a finding that could pave the way toward using it to treat obesity and related metabolic conditions.

5 Oct 2023

GLP-1 agonists linked to higher risk for gastrointestinal complications

They're being hailed as an effective way to lose weight, but diabetes drugs like Ozempic may come with a heightened risk of severe gastrointestinal problems.

5 Oct 2023

New drug tirzepatide equally effective in early-onset and later-onset type 2 diabetes

Tirzepatide is as effective at treating early-onset type 2 diabetes (T2D), a more aggressive form of the condition that normally responds less well to treatment, as it is at treating T2D diagnosed later in life, new research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany (2-6 Oct) has found.

4 Oct 2023

Experts to discuss if lasting remission from diabetes is feasible in real-world setting

At this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany (2-6 Oct) experts will discuss if lasting remission from diabetes is feasible in the real-world setting.

4 Oct 2023

Sphere Fluidics’ Cyto-Mine system selected by FairJourney Biologics to advance cell line development workflows

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, today announced the Cyto-Mine® platform has been selected by FairJourney Biologics, a world leading end-to-end antibody partner, providing integrated services across antibody discovery, engineering, and production, to expand its cell line development capabilities.

From Sphere Bio 4 Oct 2023

How do different polyphenol-rich foods impact chronic diseases?

The potential of phytochemicals in promoting a healthy human diet to combat chronic disease.

27 Sep 2023

Understanding how exercise suppresses appetite could pave the way for new obesity drugs

The complex relationship between physical activity and energy balance – food intake versus energy expenditure – is still a challenge for science, especially in light of the rising worldwide prevalence of overweight and obesity

26 Sep 2023

Research could lead to the development of new weight-loss drug that mimics exercise

A brand-new kind of drug, tested in mice, shows promising new results that could lead to the development of a new weight-loss drug that mimics exercise.

25 Sep 2023

Tirzepatide outshines other treatments in lowering blood sugar and weight for type 2 diabetes patients

Meta-analysis finds tirzepatide to be the most effective GLP-1 receptor agonist for glucose and weight control in type 2 diabetes patients. The study suggests tirzepatide could be preferable in initial stages of the disease, while other GLP-1 receptor agonists combined with insulin are equally effective for long-term diabetics.

25 Sep 2023

Could metformin be a game changer for heart health in non-diabetics?

Using Mendelian randomization, researchers found that altering seven metformin targets led to improved blood pressure and BMI in non-diabetic individuals. The study suggests the potential for metformin's role in reducing cardiovascular risks in the general population, although more research is needed.

24 Sep 2023

Tirzepatide superior to semaglutide for blood sugar control and body weight loss

A new meta-analysis combining 22 studies, to be presented at this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany (2-6 October), shows that tirzepatide is superior to semaglutide for both control of blood sugar and in terms of amount of body weight lost by patients.

22 Sep 2023

Research reveals racial and ethnic disparities in the benefits of newer type 2 diabetes drugs

New research analyzing the effects of two drugs used to treat type 2 diabetes indicates a consistent lack of cardiovascular and renal benefits in Black populations.

21 Sep 2023

Semaglutide News and Research

Latest Semaglutide News and Research

Oral diabetes and obesity meds danuglipron and orforglipron show promise but have gastrointestinal drawbacks

Skyrocketing demand for weight-loss drugs prompts calls for informed prescribing

Tirzepatide boosts weight loss in lifestyle intervention patients, but comes with a catch

Presidential advisory by the American Heart Association: connecting cardiovascular, kidney, and metabolic health

Black Chokeberry (Aronia melanocarpa) diabetes benefits: Hope or hype?

Health experts redefine cardiovascular disease risk, prevention and management

How is TikTok's #Ozempic trend impacting diabetes patients?

GLP-1 weight loss drugs linked to heightened GI risks, says new study

New findings about nerve pathways to brown fat could lead to obesity treatments

GLP-1 agonists linked to higher risk for gastrointestinal complications

New drug tirzepatide equally effective in early-onset and later-onset type 2 diabetes

Experts to discuss if lasting remission from diabetes is feasible in real-world setting

Sphere Fluidics’ Cyto-Mine system selected by FairJourney Biologics to advance cell line development workflows

How do different polyphenol-rich foods impact chronic diseases?

Understanding how exercise suppresses appetite could pave the way for new obesity drugs

Research could lead to the development of new weight-loss drug that mimics exercise

Tirzepatide outshines other treatments in lowering blood sugar and weight for type 2 diabetes patients

Could metformin be a game changer for heart health in non-diabetics?

Tirzepatide superior to semaglutide for blood sugar control and body weight loss

Research reveals racial and ethnic disparities in the benefits of newer type 2 diabetes drugs

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Semaglutide News and Research

Latest Semaglutide News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Newsletters you may be interested in